Plain-English translation of NCT06848946 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether adding iDose® TR (travoprost intracameral implant) during cataract surgery can better lower eye pressure than cataract surgery by itself. The implant is a tiny device placed inside the eye that slowly releases medication to help control glaucoma or ocular hypertension. Researchers want to see if this combination approach is safer and more effective than surgery alone.
Many patients with glaucoma need both cataract surgery and eye pressure medication. This trial exists to find out whether the medication implant can do double duty—fixing the cataract and controlling eye pressure at the same time—so patients might need fewer separate treatments.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will undergo cataract surgery and randomly receive either the new medication implant or a sham procedure (a mock procedure with no active treatment). Neither you nor your doctors will know which group you're in during the study. You will have follow-up visits to check your eye pressure, eye health, and safety over time.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States
Phase
Post-approval monitoring
Sponsor
Glaukos Corporation
Enrollment target
~132 participants
Started
January 2025
Primary completion
August 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
45 Years and older
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Study Manager
Glaukos Corporation
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.